Datapoint: Keytruda Scores Major Kidney Cancer Nod

Keytruda’s latest FDA nod could give Merck a blockbuster edge in kidney cancer, as the PD-1 inhibitor on Nov. 18 became the first immunotherapy approved to treat early renal cell carcinoma at intermediate-high or high risk of recurrence. Renal cell carcinoma is the most common form of kidney cancer. Keytruda, in combination with Pfizer’s Inlyta, was initially approved as a first-line treatment for kidney cancer in August 2019. It holds covered or better status for 83% of all insured lives under the medical benefit, compared to 71% under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 11/22/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 19

Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 18

Datapoint: CDPHP Selects New PBM

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 17

Datapoint: Oscar to Exit Two States

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today